Northwestern Mutual Wealth Management Co. Buys 85,036 Shares of Halozyme Therapeutics, Inc. $HALO

Northwestern Mutual Wealth Management Co. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 19,326.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 85,476 shares of the biopharmaceutical company’s stock after purchasing an additional 85,036 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Halozyme Therapeutics were worth $5,753,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Empowered Funds LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $755,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $195,000. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after purchasing an additional 5,448 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Finally, Baird Financial Group Inc. increased its holdings in shares of Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 650 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $68.32 on Friday. The stock has a market cap of $8.10 billion, a P/E ratio of 24.58, a PEG ratio of 0.28 and a beta of 0.89. The company’s 50-day simple moving average is $65.74 and its 200 day simple moving average is $68.75. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on HALO. Benchmark boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Wells Fargo & Company upped their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Finally, Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $80.67.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $53,122,698.20. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the sale, the director directly owned 38,498 shares in the company, valued at $2,443,853.04. This represents a 4.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.